glp 1 and kidney transplant glp-1 outcomes news today Receptor Agonist Use in Recipients in: Kidney Volume 17 Issue 8 (2025) GLP-1 receptor agonist versus DPP-4 – Use of glucagon-like peptide type

Countless Canadians use glutathione treatments for relief of psoriasis and other skin related conditions

Diabetes Spend Is Growing 4 Slower Than Non-Diabetic Costs: What the Data Shows The financial data shows an unmistakable shift: Annual spend for diabetics increased just 11% from 2021-2024 , while spend for non-diabetics jumped 15% Average monthly medical spend for diabetics decreased slightly (0.5%) , while non-diabetic medical spend surged 17% Prescription growth for diabetics (34%) stayed well below the 57% spike for non-diabetics For the first time, diabetic spend is flattening faster than non-diabetic spendcompletely reversing the previous pattern where diabetes costs outpaced everything else by 2x

However, its important to note: Weight management can be a valuable secondary outcome for people with T2DM, as it often improves insulin sensitivity, lowers cardiovascular risk, and enhances overall metabolic health 4 , 10

In the perspective, the team noted that the GLP-1RA class of medications is transforming the care of obesity and type 2 diabetes in adults and noted recent studies indicating similar powerful effects in children and adolescents

GLP-1 drug shows little benefit for people with Parkinsons disease 5 February 2025 The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinsons disease, finds a new study led by UCL researchers

doi: 10.1038/nature12306 18 IshikawaHBarberGN